Answers are grounded in this paper and cite their sources.
Enarodustat was noninferior to DA for the treatment of anemia in CKD patients receiving maintenance hemodialysis and was generally well tolerated over 24 weeks.
No takes yet. Share an insight, caveat, or question.
Akizawa et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: